The United States Patent and Trademark Office (USPTO) has issued a patent grant, US12583919B2, to Antlera Therapeutics Inc. This patent covers novel antibodies that specifically bind to LRP6 proteins, along with associated methods of use. The patent application was filed on August 14, 2020, and the grant is effective March 24, 2026.

This patent grant signifies the protection of intellectual property related to specific therapeutic antibodies. While not imposing direct compliance obligations on other entities, it establishes exclusive rights for Antlera Therapeutics Inc. in the claimed inventions. Companies operating in the therapeutic antibody space, particularly those targeting LRP6 proteins or related pathways, should be aware of this patent to avoid potential infringement and to inform their own research and development strategies.